Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene (Q44124151)

30 November 2017

title

Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene (English)

1 reference

30 November 2017

1

Timothy M Pawlik

1 reference

30 November 2017

Hideo Nakamura

2

1 reference

30 November 2017

John T Mullen

3

1 reference

30 November 2017

Hideki Kasuya

4

1 reference

30 November 2017

Sam S Yoon

5

1 reference

30 November 2017

Soundararajalu Chandrasekhar

6

1 reference

30 November 2017

E Antonio Chiocca

7

1 reference

30 November 2017

Kenneth K Tanabe

8

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

30 November 2017

1 reference

30 November 2017

volume

95

1 reference

30 November 2017

issue

5

1 reference

30 November 2017

page(s)

1171-1181

1 reference

30 November 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Regression of established macroscopic liver metastases after in situ transduction of a suicide gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: implications for autologous vaccine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Combination gene therapy for liver metastasis of colon carcinoma in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Reovirus therapy of tumors with activated Ras pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Newcastle disease virus (NDV): brief history of its oncolytic strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Drug-metabolizing enzyme expression in human normal, peritumoral and tumoral colorectal tissue samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Retrovirally transmitted gene therapy for gastric carcinoma using herpes simplex virus thymidine kinase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Metabolism of oxazaphosphorines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Studies on the use of viruses in the treatment of carcinoma of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Prodrug-activating systems in suicide gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

7 January 2021

Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

7 January 2021

Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

7 January 2021

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

7 January 2021

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10776

7 January 2021

Identifiers

DOI

10.1002/CNCR.10776

1 reference

30 November 2017

1 reference